Literature DB >> 24266814

Biomarkers for prostate cancer: who will benefit from local treatment, who harbors occult systemic disease and who needs treatment at all?

Deborah Citrin1, Kevin A Camphausen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24266814      PMCID： PMC6368180          DOI： 10.2217/bmm.13.127

Source DB:  PubMed          Journal:  Biomark Med        ISSN： 1752-0363            Impact factor:   2.851


× No keyword cloud information.
  18 in total

1.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Authors:  Scott A Tomlins; Daniel R Rhodes; Sven Perner; Saravana M Dhanasekaran; Rohit Mehra; Xiao-Wei Sun; Sooryanarayana Varambally; Xuhong Cao; Joelle Tchinda; Rainer Kuefer; Charles Lee; James E Montie; Rajal B Shah; Kenneth J Pienta; Mark A Rubin; Arul M Chinnaiyan
Journal:  Science       Date:  2005-10-28       Impact factor: 47.728

Review 2.  The development of nomograms for stratification of men at risk of prostate cancer prior to prostate biopsy.

Authors:  Marianne Schmid; Jens Hansen; Micheal Rink; Margit Fisch; Felix Chun
Journal:  Biomark Med       Date:  2013-12       Impact factor: 2.851

Review 3.  Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management.

Authors:  Sadhna Verma; Baris Turkbey; Naira Muradyan; Arumugam Rajesh; Francois Cornud; Masoom A Haider; Peter L Choyke; Mukesh Harisinghani
Journal:  AJR Am J Roentgenol       Date:  2012-06       Impact factor: 3.959

Review 4.  Cancer treatment and survivorship statistics, 2012.

Authors:  Rebecca Siegel; Carol DeSantis; Katherine Virgo; Kevin Stein; Angela Mariotto; Tenbroeck Smith; Dexter Cooper; Ted Gansler; Catherine Lerro; Stacey Fedewa; Chunchieh Lin; Corinne Leach; Rachel Spillers Cannady; Hyunsoon Cho; Steve Scoppa; Mark Hachey; Rebecca Kirch; Ahmedin Jemal; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2012-06-14       Impact factor: 508.702

Review 5.  Cell mates: paracrine and stromal targets for prostate cancer therapy.

Authors:  Pavel Sluka; Ian D Davis
Journal:  Nat Rev Urol       Date:  2013-07-16       Impact factor: 14.432

6.  Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer.

Authors:  Jianghua Wang; Yi Cai; Chengxi Ren; Michael Ittmann
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

7.  Cancer statistics, 2012.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2012-01-04       Impact factor: 508.702

8.  Contemporary risk profile of prostate cancer in the United States.

Authors:  Yu-Hsuan Shao; Kitaw Demissie; Weichung Shih; Amit R Mehta; Mark N Stein; Calpurnyia B Roberts; Robert S Dipaola; Grace L Lu-Yao
Journal:  J Natl Cancer Inst       Date:  2009-08-27       Impact factor: 13.506

9.  Clinical significance of both tumor and stromal expression of components of the IL-1 and TNF-α signaling pathways in prostate cancer.

Authors:  Gonzalo Rodríguez-Berriguete; Beatriz Sánchez-Espiridión; José R Cansino; Gabriel Olmedilla; Pilar Martínez-Onsurbe; Manuel Sánchez-Chapado; Ricardo Paniagua; Benito Fraile; Mar Royuela
Journal:  Cytokine       Date:  2013-09-21       Impact factor: 3.861

10.  Urinary aHGF, IGFBP3 and OPN as diagnostic and prognostic biomarkers for prostate cancer.

Authors:  Alisa J Prager; Cynthia R Peng; Elena Lita; Debbie McNally; Aradhana Kaushal; Mary Sproull; Kathryn Compton; William L Dahut; William D Figg; Deborah Citrin; Kevin A Camphausen
Journal:  Biomark Med       Date:  2013-12       Impact factor: 2.851
View more
  1 in total

1.  Magnetic nanoparticle hyperthermia enhances radiation therapy: A study in mouse models of human prostate cancer.

Authors:  Anilchandra Attaluri; Sri Kamal Kandala; Michele Wabler; Haoming Zhou; Christine Cornejo; Michael Armour; Mohammad Hedayati; Yonggang Zhang; Theodore L DeWeese; Cila Herman; Robert Ivkov
Journal:  Int J Hyperthermia       Date:  2015-03-26       Impact factor: 3.914
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.